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Management of Parkinson’s Disease
During Pregnancy: Literature Review
and Multidisciplinary Input
Caitlin Young, MD,1,* Rhiannon Phillips, PhD,2 Louise Ebenezer, MSc,3 Rodi Zutt, MD, PhD,4 and Kathryn J. Peall, MD, PhD5,*
ABSTRACT: Background: There are no standardized clinical guidelines for the management of Parkinson’s
disease (PD) during pregnancy. Increasing maternal age would suggest that the incidence of pregnancy in
women diagnosed with PD is likely to increase.
Objective: To evaluate the evidence for the treatment of PD during pregnancy and to canvass opinion from
patients and clinical teams as to the optimum clinical management in this setting.
Methods: This involved (1) a literature review of available evidence for the use of oral medical therapy for the
management of PD during pregnancy and (2) an anonymized survey of patients and clinical teams relating to
previous clinical experiences.
Results: A literature review identified 31 publications (148 pregnancies, 49 PD, 2 parkinsonism, 21 dopa-
responsive dystonia, 32 restless leg syndrome, 1 schizophrenia, and 43 unknown indication) detailing treatment
with levodopa, and 12 publications with dopamine agonists. Adverse outcomes included seizures and
congenital malformations. Survey participation included patients (n = 7), neurologists (n = 35), PD nurse
specialists (n = 50), obstetricians (n = 15), and midwives (n = 20) and identified a further 34 cases of pregnancy
in women with PD. Common themes for suggested management included optimization of motor symptoms,
preference for levodopa monotherapy, and normal delivery unless indicated by obstetric causes.
Conclusions: This study demonstrates the paucity of evidence for decision-making in the medical management
of PD during pregnancy. Collaboration is needed to develop a prospective registry, with longitudinal maternal
and child health outcome measures to facilitate consensus management guidelines.
Approximately 5% of Parkinson’s disease (PD) diagnoses are made
in individuals younger than 40 years, meaning that women with
early-onset PD may become pregnant after diagnosis.1 The inci-
dence of pregnancy in women with PD is unclear, although it is
likely to rise given the trend toward increasing maternal age and
that no data to date indicate a reduction in fertility for those
women diagnosed with PD.2 Previous case series have docu-
mented fetal and maternal outcomes in multiple pregnancies,
including adverse events such as spontaneous abortion. However,
information about the use and safety of medication for the treat-
ment of PD during pregnancy is largely anecdotal and lacks long-
term follow-up maternal and child outcome data. The lack of
evidence-based practice and standardized clinical guidelines means
that clinicians and women with PD face uncertainty as to how
best to plan care during this period. This study seeks to evaluate
and summarize currently available evidence for the management
of PD during pregnancy and to determine the experiences of both
patients and clinical teams in this clinical setting.
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Methods
This study includes (1) a structured literature review of available evi-
dence relating to the use of medication and deep brain stimulation
(DBS) to treat PD during pregnancy and (2) a survey of patient and
clinical team experiences of PD management during pregnancy.
Literature Search
Our literature review aimed to address the obstetric outcomes when
medication and/or DBS were used to treat PD during pregnancy and
to assess the quality of evidence against GRADE criteria (grading of
Recommendations, Assessments, Development and Evaluation).
Reports meeting the following criteria were eligible for inclusion:
(1) those relating to the use of levodopa, dopamine agonist, mono-
amine oxidase-B (MAO) inhibitors, or catechol-O-methyl-transferase
(COMT) inhibitors or antimuscarinic therapy in pregnant women,
irrespective of diagnosis, as well as DBS for those with a diagnosis of
PD; (2) an English-language abstract; (3) data and observations from
pregnancy in humans rather than other mammalian species. To maxi-
mize reach, data relating to the use of PD therapies in other
dopamine-responsive conditions such as restless leg syndrome and
dopa-responsive dystonia were also included. No restriction was
placed on the date of publication, with information sourced using the
MEDLINE and Web of Science databases. Additional articles were
also identified from the reference list of screened articles. The database
search strategy is summarized in Supplementary Figure S1. Those arti-
cles included were subsequently divided into case reports, small case
series (n < 5), large case series (n > 5), and larger observational studies
(Supplementary Table S1). The information collated included name
or class of dopaminergic medication, number of pregnancies exposed,
reason for treatment (maternal diagnosis), and pregnancy outcome.
The GRADE criteria were used to assess the quality of evidence relat-
ing to each treatment with the summary measure determined by the
total number of live births, spontaneous abortions, terminations of
pregnancy, and still births with each form of therapy.
Survey Data Collection
Via an online survey, data were collected on the following 5 key
domains: (1) medication to treat PD symptoms, (2) PD symptoms
during pregnancy, (3) organization of clinical care, (4) adverse
obstetric events and delivery, (5) postpartum period. Informed
consent was obtained from 5 groups: individuals diagnosed with
PD who had been pregnant since diagnosis, neurologists, obstetri-
cians, midwives, and PD specialist nurses. The organizations
involved in contacting these groups are summarized in Supple-
mentary Figure S2. Health care professionals without previous
clinical experience in this setting were also invited to share
suggested management plans to gain a wider context of opinion.
Data Analysis
Nominal and multiple-choice survey responses were analyzed
descriptively. Open-text responses were coded according to con-
tent, and an inductive, data-driven coding approach employed.
Content analysis identified key themes, and constant comparison
enabled a search for emerging themes.
Results
Literature Review: Clinical
Evidence for the Use of
Antiparkinsonian Medication
During Pregnancy
Supplementary Table S1 and Table 1 summarize the publications
reviewed and outcomes, respectively.3–40,42 In brief, 31 publications
reported the use of levodopa in 148 pregnancies, with examples of
reported adverse outcomes including congenital malformation
(n = 8) and seizures.4–7 Two publications provided results of
genetic testing, including a total of 4 cases with Parkin muta-
tions.21,22 Of the 109 levodopa-exposed pregnancies for which
outcomes were available, 83% resulted in live births (n = 91), 8%
were electively terminated (n = 9), and 9% resulted in spontaneous
abortion (n = 10). Fewer publications included the use of dopa-
mine agonists (n = 12), antimuscarinic medication (n = 4), COMT
inhibitors (n = 4), monoamine-oxidase B inhibitors (n = 3), and
DBS (n = 4). The largest case series of DBS during pregnancy iden-
tified 11 individuals with 18 births (PD = 3, dystonia = 5, Tour-
ette’s syndrome = 2, obsessive-compulsive disorder = 1). Of the
3 cases diagnosed with PD, 1 stopped her medication during preg-
nancy and resumed at the same dose postpartum, another changed
from a dopamine agonist to levodopa and back to a dopamine ago-
nist postpartum, and the third continued her treatment of a dopa-
mine agonist and MAO inhibitor throughout.21 None of these
women breastfed in the postpartum period owing to concerns of
the impact of their oral medical therapy. The quality of evidence is
summarized according to the GRADE criteria (Table 2).
Survey Outcomes: Patients,
Neurologists, PD Nurse
Specialists, Obstetricians, and
Midwives
Our survey identified 34 pregnancies in women with PD, with
medication continued in 15, and 2 reported complications
(Table 2).
Women Diagnosed with PD with
Subsequent Pregnancy
A total of 7 women completed our survey regarding 10 pregnan-
cies, resulting in 8 healthy live births, 1 stillbirth (24 weeks), and
1 pregnancy with unknown outcome (Table 2). Three women
were diagnosed with PD during pregnancy (20–48 years), and
3 women received oral medical therapy during 4 pregnancies.
One patient reported an improvement in motor symptoms
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despite withdrawal of all PD medications during this period.
Two patients (2 and 6) required oral medical therapy postpartum
due to worsening motor symptoms.
Neurologists
A total of 35 neurologists responded to our survey, 8 of whom
had experience caring for women with PD during 12 pregnancies
(Table 3 and Supplementary Table S2). Management suggestions
included reviewing medication safety and using as few medica-
tions as possible, particularly preconception and during the first
trimester. Emphasis was placed on maintaining good motor
symptom management during pregnancy, and if required oral
levodopa monotherapy was preferred. They also suggested regu-
lar review, referral to specialist movement disorder clinics during
the antepartum period, and close working with other members
of the multidisciplinary team.
PD Nurse Specialists
A total of 50 responses were obtained, 5 of whom had experi-
ence of caring for patients with PD during 8 pregnancies
(Table 3 and Supplementary Table S2). Suggestions focused on
the antenatal period, including reviewing medication and aiming
to minimize oral medical therapy. There was wide support for
adopting a multidisciplinary approach (n = 19). Suggestions for
organization of care included open access to neurology services
(n = 1) and more frequent monitoring (n = 6).
Obstetricians
Fifteen responses were obtained from obstetricians, with 2 having
had experience managing 4 pregnancies in mothers with PD
(Table 3 and Supplementary Table S2). Twelve suggested obstet-
ric led care due to the unknown medication risk in pregnancy
and the potential for worsening motor symptoms. There was
consensus that a normal schedule of antenatal appointments
should be followed with increased review if problems arose.
Additional recommendations included prepregnancy counseling,
monthly joint clinics with the neurology team, and coordination
of antenatal appointments with fetal growth scans. None advised
delivery by caesarean section, with this being reserved for obstet-
ric indications only. Suggestions for postpartum management
included standard care, inpatient neurology review within
24 hours of delivery, and obstetric high-dependency monitoring.
Midwives
A total of 20 midwives responded to the survey, none of whom
had experience of caring for women with PD during pregnancy.
Seventeen shared suggestions for pregnancy care
(Supplementary Table S2. Antenatally, these included the fol-
lowing: obstetric-led care (n = 7), multidisciplinary team
approach (n = 8), involvement of physiotherapists to aid balance
difficulties (n = 4), and the offer of home visits to avoid long
waits in antenatal clinics (n = 2). Active, mobile labor was
advised, although the potential for women to tire, guided by
their experience of other chronic disorders, was highlighted
alongside the midwifery preference for delivery in an obstetric
unit or midwife-led unit alongside an obstetric center.
Discussion
This study represents the first to synthesize evidence relating to
clinical outcomes of the management of PD during pregnancy
and investigate care experiences from patient and multi-
disciplinary team perspectives.
Medication During Pregnancy
Literature Review
Our literature review demonstrates the paucity of evidence for
the safety of dopaminergic therapy during pregnancy, with levo-
dopa the preferred form of treatment. Ten pregnancies, from a
total of 148, resulted in spontaneous abortion (9.2%), and 3 live
births were associated with fetal congenital abnormalities includ-
ing patent foramen ovale and ductus arteriosus.3 The rates of
clinically recognized pregnancies resulting in fetal loss in the gen-
eral population are estimated to be 10% to 24%, indicating no
excess rate among this patient group, particularly in the context
of exposure to levodopa therapy.41 Fewer studies related to the
use of dopamine agonists, antimuscarinic drugs, and COMT and
MOA-B inhibitors during pregnancy, and therefore estimates of
fetal loss are more difficult to determine. Spontaneous abortion
was reported in 4 cases of pramipexole monotherapy.3,42
Our literature search also included data relating to the use of
medication in the treatment of other dopamine-responsive disor-
ders during pregnancy such as restless legs syndrome and dopa-
responsive dystonia. The underlying aetiology of these disorders
is distinct from that of PD and may independently impact preg-
nancy irrespective of medication. There was substantial variation
in the dose of all prescribed medication (Table 1) and under-
standing of the risk of obstetric complications is limited by the
majority of evidence provided in the form of case reports. Fur-
thermore, PD medications were frequently coprescribed, making
it difficult to elucidate the effects of individual drugs. Four publi-
cations relating to the use of DBS during 23 pregnancies were
also identified (Supplementary Table S1). All operations were
undertaken prepregnancy with 23 live births and 1 spontaneous
abortion in the first few weeks of pregnancy reported. No com-
plications with the use of DBS during pregnancy were reported.
Multidisciplinary Survey Outcomes
Our survey found 88.2% (n = 30/34) of the identified pregnan-
cies resulted in a live birth, and 5.9% (n = 2/34) ended in spon-
taneous abortion, below the estimated rates in the general
population.41 Where medication was continued, there was a
preference for levodopa. However, these results are retrospec-
tively reported, and due to recruitment methods, potentially not
MOVEMENT DISORDERS CLINICAL PRACTICE 2020; 7(4): 419–430. doi: 10.1002/mdc3.12925 427
C. YOUNG ET AL. RESEARCH ARTICLE
representative of the spectrum of women diagnosed with PD
who have subsequently become pregnant.
Parkinson’s Symptoms During
Pregnancy
Published literature to date suggests that women experience varia-
tion in their PD symptoms during pregnancy, with early reports
suggesting that 65% of women experienced worsening of their
symptoms despite the continuation of medical therapy.12 The
physiological mechanisms by which pregnancy can result in symp-
tomatic change is poorly understood. Altered pharmacokinetics
due to the expansion in plasma volume may reduce peak serum
concentrations of oral medical therapy, whereas changes to gastro-
intestinal absorption and increases in estimated glomerular filtration
rate (eGFR) may affect the availability and renal elimination of
drugs.43 In keeping with this, our survey identified variation in the
evolution of motor symptoms during the course of pregnancy,
although this may have related to a number of factors, including
ongoing adjustments to the dose of medical therapy for which no
serum measurements were available.1
Half of the women surveyed noted worsening of symptoms
during pregnancy, 13 reported no change, and 1 patient reported
an overall improvement in motor symptoms, mood, and energy
levels during 2 pregnancies. Where symptoms worsened, 60%
(n = 9) did so after all or adjuvant medications were withheld or
doses reduced, whereas 25% (n = 4) noted symptom worsening
while receiving treatment with levodopa monotherapy. Only
15% (n = 2) of women whose symptoms worsened did so
despite no change to PD medications. These reports suggest that
although PD symptoms during pregnancy are likely to vary
between individuals, the maintenance of at least prepregnancy
treatment levels is likely to limit symptomatic fluctuation.
Organization of Care
Studies of other chronic disorders (eg, rheumatoid arthritis) in
pregnancy emphasize the need for well-coordinated multi-
disciplinary involvement, with decision aids demonstrating
enhanced shared decision-making.44 Despite this, there are no
currently available guidelines on obstetric best practice in the
management of PD during pregnancy, and only 2 patients in this
cohort received more frequent antenatal neurology input. All of
the obstetricians consulted felt that antenatal care should be con-
sultant led and follow a normal schedule of antenatal appoint-
ments. Although joint obstetric/neurology review was only
undertaken in 3 cases in this study, both clinician groups advo-
cated enhanced communication between teams.
Adverse Events and Delivery
To date, there is no evidence to suggest higher rates of fetal or
maternal complications, fertility difficulties, or birth-related com-
plications in women with PD.1 Obstetrician responses in this sur-
vey felt there was no indication to alter the standard of
postpartum care (4/15 [27%]) and that a diagnosis of PD would
not contraindicate vaginal delivery, suggesting that delivery by
caesarean section should be reserved for obstetric indications
only. Information relating to the mode of delivery was available
for 12 pregnancies: 8 vaginal deliveries, 2 emergency caesarean
sections (17%), and 2 assisted deliveries (17%). The rate of emer-
gency caesarean section is ~15% in the United Kingdom, broadly
comparable with that observed in our data set.45
Postpartum Period,
Breastfeeding, and Support
The challenges facing new mothers with PD are poorly under-
stood, with deteriorating fine motor skills often presenting func-
tional difficulties in undertaking daily tasks. Decisions relating to
breastfeeding are complicated by limited information regarding
the potential risk of medication to infants, although plasma and
breastmilk levodopa concentrations in a single study estimated
the level of exposure to be low (0.016–0.023 mg/kg/day).24
The inhibitory effects of levodopa and dopamine agonists on
prolactin synthesis suggests they may suppress lactation, although
2 women in this cohort were able to breastfeed for a
limited time.
Conclusion
This study has collated information from a number of distinct
sources, highlighting several key aspects. The majority of outcome
data for pregnancies of women diagnosed with PD are linked with
use of levodopa treatment during this period, with outcome data
only available in a small number of cases for those treated with
other forms of dopaminergic therapy. The results from our system-
atic review indicate no excess rates of miscarriage, stillbirth, or con-
genital deformity among this patient group compared with the
general population. Patient and multi-disciplinary team (MDT)
survey responses suggest that an optimized care plan would include
close cooperation between neurology and obstetric teams during
pregnancy and delivery. However, the most important element
highlighted is the need for an international prospective registry for
women diagnosed with PD during and after pregnancy, similar to
those for other chronic neurological disorders. A registry would aid
in the development of consensus guidelines for clinical care in this
setting and provide longer term follow-up data on infant and child-
hood development to better aid therapeutic decision-making.
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Supplementary Figure S1. Schematic representation of the
search terms used during the systematic literature review. Blue
boxes represent the research terms used and number of publica-
tions identified. Green boxes represent additional publications
identified, and orange boxes are those excluded as they were
not considered relevant to this review. Articles were divided
into case reports (n = 1), smaller case series (n < 5), and larger
case series or cohort studies (n > 5). COMT inhibitor,
catechol-O-methyl-transferase inhibitor; MAOI, monoamine-
oxidase inhibitors.
Supplementary Figure S2. Schematic representation or
sources of participant recruitment from clinical and patient sec-
tors (green, patient recruitment; orange, neurology recruitment;
blue, Parkinson’s disease nurse specialist recruitment; yellow,
midwifery recruitment; purple, obstetric recruitment).
Supplementary Table S1. Details of publications identified
in systematic literature review.
Supplementary Table S2. Summary of questionnaire free-text
responses.
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